{"gene":"GFAP","run_date":"2026-06-10T01:55:21","timeline":{"discoveries":[{"year":1985,"finding":"GFAP is the major protein constituent of glial intermediate filaments in differentiated fibrous and protoplasmic astrocytes of the CNS, functioning as a cytoskeletal component that defines and maintains the shape of astrocytes.","method":"Biochemical characterization, immunochemical and immunocytochemical studies","journal":"Journal of neuroimmunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — extensively replicated across hundreds of labs using multiple orthogonal methods over decades; foundational characterization of GFAP as the structural IF protein of astrocytes","pmids":["2409105"],"is_preprint":false},{"year":1985,"finding":"Dibutyryl cyclic AMP (dbcAMP) increases GFAP synthesis in cultured astrocytes, as demonstrated by radioactive methionine labeling showing increased GFAP and vimentin synthesis within 48 h of exposure.","method":"Radioactive metabolic labeling of primary astrocyte cultures treated with dbcAMP","journal":"Journal of neuroimmunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct biochemical labeling experiment in primary cultures, single lab but clear mechanistic readout","pmids":["2989328"],"is_preprint":false},{"year":1989,"finding":"Schwann cell expression of GFAP is developmentally regulated and requires continued trophic input from small axons; sciatic nerve transection causes marked reduction in GFAP mRNA in the distal stump, demonstrating axon-dependent regulation of GFAP in peripheral glia.","method":"Northern blot of sciatic nerve RNA after nerve transection; immunohistology of teased nerve fascicles","journal":"Journal of neuroscience research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct loss-of-function (transection) with defined molecular readout (mRNA reduction), single lab","pmids":["2769798"],"is_preprint":false},{"year":1990,"finding":"GFAP turnover in cultured astrocytes is biphasic, with a fast-decaying pool (half-life ~16–18 h) and a stable pool (half-life ~5–6 days); the stable pool increases proportionally as astrocytes mature, reflecting dynamic regulation of GFAP during differentiation.","method":"Pulse-chase radiolabeling of primary astroglial cultures at different developmental stages","journal":"Brain research. Developmental brain research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — quantitative kinetic pulse-chase experiment in primary cultures, single lab","pmids":["2279327"],"is_preprint":false},{"year":1991,"finding":"Insulin-related peptides regulate GFAP expression and astrocyte morphology in organotypic cerebellar cultures; high insulin levels increase GFAP mRNA and protein with enrichment of radial glial morphology, while low insulin levels produce undifferentiated epithelioid cells with minimal GFAP expression.","method":"Organotypic cultures of E17 mouse cerebellum with varying insulin concentrations; non-isotopic in situ hybridization for GFAP mRNA; GFAP immunoreactivity","journal":"Brain research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — two orthogonal methods (ISH + immunostaining) in a defined culture system, single lab","pmids":["1782546"],"is_preprint":false},{"year":1994,"finding":"A 2.2 kb 5'-flanking sequence of the human GFAP gene is sufficient to direct astrocyte-specific expression in transgenic mice and recapitulates injury-induced upregulation of GFAP, demonstrating that key transcriptional regulatory elements reside in this promoter region.","method":"Transgenic mice carrying GFAP-promoter-lacZ reporter; histochemical staining after CNS injury","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo transgenic reporter system replicated across multiple labs; key promoter element functionally validated","pmids":["8120611"],"is_preprint":false},{"year":1998,"finding":"TGF-β1 significantly increases GFAP mRNA and protein in astrocytes, while FGF-2 significantly decreases GFAP mRNA and protein and inhibits TGF-β1-mediated increases; FGF-2 effects are blocked by an FGFR tyrosine kinase inhibitor, indicating receptor-mediated signaling.","method":"Primary astrocyte cultures treated with TGF-β1 and FGF-2; Western blot and mRNA analysis; pharmacological inhibition with 5'-methylthioadenosine and cycloheximide","journal":"Glia","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple pharmacological manipulations with mRNA and protein readouts in primary cultures, single lab","pmids":["9537840"],"is_preprint":false},{"year":1999,"finding":"Neurons secrete brain-region-specific soluble factors that activate the GFAP gene promoter in astrocytes, inducing glial differentiation and cell cycle arrest, as demonstrated using transgenic astrocytes carrying a GFAP promoter-β-galactosidase reporter.","method":"Co-culture of neurons and transgenic astrocytes (GFAP-promoter-β-gal reporter mice); conditioned medium experiments; cell cycle analysis","journal":"Glia","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter gene system with conditioned medium controls, defined cellular phenotype, single lab","pmids":["10384875"],"is_preprint":false},{"year":2002,"finding":"GFAP coding mutations in Alexander disease are heterozygous missense mutations found in the 1A, 2A, and 2B rod domains and the tail region; all are de novo dominant mutations, and the disease likely results from a dominant gain-of-function (partial block of filament assembly leading to accumulation of a toxic intermediate) rather than dominant loss-of-function, since GFAP null mice do not display Alexander disease symptoms.","method":"Sequencing of GFAP coding regions from Alexander disease patients; genetic analysis of multiple disease cases; comparison with GFAP null mouse phenotype","journal":"International journal of developmental neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — replicated across multiple labs; null mouse phenotype provides epistatic evidence; gain-of-function mechanism supported by multiple independent patient analyses","pmids":["12175861"],"is_preprint":false},{"year":2003,"finding":"GFAP contains novel splice forms (Δ135 nt, Δexon 6, Δ164 nt) expressed as out-of-frame variants in neurons (pyramidal neurons of hippocampus), particularly associated with Alzheimer's disease pathology and Down syndrome, demonstrating cell-type-specific alternative splicing of GFAP.","method":"RT-PCR identification of novel splice variants; immunohistochemistry on human hippocampal tissue from AD, Down syndrome, and control cases","journal":"Molecular psychiatry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — two orthogonal methods (molecular cloning + immunohistochemistry), single lab","pmids":["12931206"],"is_preprint":false},{"year":2005,"finding":"The Alexander disease-causing R239C mutation in GFAP causes filament disorganization and decreased solubility: in SW13Vim(-) cells R239C GFAP forms diffuse/irregular rather than filamentous networks, and Triton-X-100 extraction shows R239C GFAP is more resistant to solubilization. Both wild-type and R239C GFAP assemble into 10 nm filaments in vitro with similar morphology, indicating the mutation affects network organization and solubility rather than filament formation per se.","method":"Transient transfection of R239C GFAP into SW13Vim(-) cells, primary rat astrocytes, Cos-7 cells; Triton-X-100 extraction; in vitro filament assembly assay","journal":"Journal of cell science","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution of filament assembly combined with cell-based solubility assay and mutagenesis; multiple cell systems tested in one study","pmids":["15840648"],"is_preprint":false},{"year":2005,"finding":"LIF signaling generates GFAP+ cells that retain progenitor characteristics (remain in cell cycle, self-renew, enhanced neurogenesis), while BMP signaling generates GFAP+ cells that are stellate, exit cell cycle, and lack progenitor traits. In vivo, transgenic BMP4 overexpression increases GFAP+ astrocytes but depletes the GFAP+ progenitor pool, while BMP inhibition has the opposite effect.","method":"Treatment of cultured embryonic SVZ progenitors with LIF or BMP; transgenic mice overexpressing BMP4 or inhibitor of BMP signaling; cell cycle analysis; immunostaining","journal":"Development","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vitro and in vivo experiments with genetic epistasis (transgenic gain and loss of BMP signaling) converging on same conclusion","pmids":["16314487"],"is_preprint":false},{"year":2007,"finding":"GFAP mutations in Alexander disease cause: (i) GFAP accumulation and Rosenthal fiber formation, (ii) sequestration of protein chaperones αB-crystallin and HSP27 into Rosenthal fibers, and (iii) activation of JNK and the stress response, collectively driving disease pathogenesis.","method":"Review synthesizing data from patient tissue, cell transfection studies, and mouse models; immunostaining for chaperones in Rosenthal fibers; JNK activation assays","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — synthesizes experimental data from multiple studies; direct co-localization and kinase activation demonstrated, but review article compiles rather than presents primary data","pmids":["17498694"],"is_preprint":false},{"year":2008,"finding":"Glutamate activates the GFAP gene promoter in astrocytes through metabotropic glutamate receptors (mGluR2/3), triggering TGF-β1 secretion, which activates Smad transcription factor nuclear translocation; MAPK and PI3K pathways are also required for TGF-β1-induced GFAP gene activation, suggesting cooperation between canonical (Smad) and non-canonical TGF-β pathways.","method":"Transgenic astrocytes with GFAP-promoter-β-gal reporter; neutralizing antibodies against TGF-β; mGluR antagonist MCPG; MAPK inhibitor PD98059; PI3K inhibitor LY294002; Smad-2 phosphorylation assay","journal":"Journal of neurochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple pharmacological inhibitors with reporter readout; mechanistic pathway defined, single lab","pmids":["18419760"],"is_preprint":false},{"year":2008,"finding":"The human GFAP promoter contains specific DNA elements required for astrocyte specificity and region-specific expression: a 45 bp sequence (bp -1443 to -1399, C1.2) is required for silencing GFAP expression in neurons, and a 55 bp segment (bp -1488 to -1434, C1.1) contains region-specific elements.","method":"Transgenic mice carrying GFAP promoter deletion constructs linked to lacZ reporter; brain region analysis of reporter expression","journal":"Glia","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo transgenic deletion analysis identifies functional promoter elements; single lab","pmids":["18240313"],"is_preprint":false},{"year":2008,"finding":"Mutant GFAP (Alexander disease), as well as excess wild-type GFAP, promotes formation of cytoplasmic inclusions, disrupts the cytoskeleton, decreases cell proliferation, increases cell death, reduces proteasomal function, and compromises astrocyte stress resistance in primary astrocyte cultures.","method":"Primary astrocyte cultures from GFAP over-expressing transgenic mice and GFAP knock-in (R236H) mice; immunostaining; proteasome activity assays; cell proliferation and death assays; stress challenge","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — two genetic mouse models with multiple cellular readouts; single lab","pmids":["19146851"],"is_preprint":false},{"year":2011,"finding":"SIN3A coupled with MeCP2 binds to the GFAP promoter to repress GFAP transcription; upon astrocyte differentiation, SIN3A-MeCP2 departs and activated STAT3 binds to the promoter and exon 1, recruiting CBP/p300 to exon 1, leading to H3K9 and H3K14 acetylation and H3K4 trimethylation that activate GFAP gene transcription.","method":"ChIP assays for SIN3A, MeCP2, STAT3, CBP/p300, RNA Pol II, histone marks; NTera-2 cell differentiation into astrocyte-like lineage","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1 / Moderate — chromatin immunoprecipitation with multiple histone mark readouts and transcription factor occupancy, mechanistically well-defined, single lab with multiple orthogonal methods","pmids":["21779366"],"is_preprint":false},{"year":2013,"finding":"GFAP promoter activity is regulated by NFI, SP1, STAT3, and NF-κB binding sites (but not the consensus AP-1 site) within the B region (bp -1612 to -1489), with each subregion contributing cooperatively to transcriptional strength and astrocyte specificity.","method":"Transgenic mice with block mutations and specific transcription factor binding site mutations in GFAP promoter-reporter constructs; analysis of expression level, brain region pattern, and astrocyte specificity","journal":"Glia","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo transgenic mutational analysis of promoter elements, single lab","pmids":["23832770"],"is_preprint":false},{"year":2013,"finding":"MeCP2 binds to methylated regions of the GFAP promoter and represses GFAP expression; siRNA knockdown of MeCP2 in the developing female rat amygdala and hypothalamus specifically increases GFAP mRNA and protein without altering other astrocyte markers (S100β, vimentin).","method":"MeCP2 siRNA infusion into rat brain; RT-PCR and Western blot for GFAP, S100β, and vimentin; sex-specific analysis","journal":"Brain research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo RNAi with specificity controls (S100β, vimentin unchanged), single lab","pmids":["24269336"],"is_preprint":false},{"year":2014,"finding":"HDAC inhibition (trichostatin A or sodium butyrate) reduces GFAP expression in human astrocytes and astrocytoma cells and increases the GFAPδ:GFAPα ratio, with the alternative isoform expression being dependent on SR protein splicing factors. HDAC inhibition also induces aggregation of the GFAP network resembling Alexander disease pathology.","method":"Primary human astrocytes and astrocytoma cells treated with HDAC inhibitors; qRT-PCR for isoforms; immunostaining for network organization; siRNA knockdown of SR proteins","journal":"Journal of cell science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple pharmacological agents plus siRNA knockdown; two orthogonal methods (mRNA and protein), single lab","pmids":["25128567"],"is_preprint":false},{"year":2014,"finding":"Shifting the GFAP isoform ratio toward GFAPδ (by shRNA silencing of GFAPα) decreases plectin expression and increases laminin expression, resulting in decreased astrocytoma cell motility. Pan-GFAP silencing leads to decreased cell spreading, increased integrin expression, and >100-fold increase in cell adhesion to laminin, demonstrating isoform-specific roles of GFAP in regulating extracellular matrix interactions.","method":"Isoform-specific shRNA silencing of GFAPα in astrocytoma cells; migration/motility assays; integrin and laminin expression analysis; cell adhesion assay","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — isoform-specific RNAi with multiple functional readouts (motility, adhesion, integrin expression), single lab","pmids":["24696300"],"is_preprint":false},{"year":2016,"finding":"GFAPδ exchanges more slowly with the intermediate filament network than GFAPα as measured by FRAP; GFAPδ-induced IF network collapse further decreases exchange rates of both isoforms and alters cell morphology and focal adhesion size without affecting cell migration or proliferation.","method":"FRAP of fluorescently tagged GFAPα and GFAPδ in astrocytoma cells; immunostaining for focal adhesions; migration and proliferation assays","journal":"Cellular and molecular life sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — quantitative live-cell FRAP with multiple functional assays, single lab","pmids":["27141937"],"is_preprint":false},{"year":2017,"finding":"Gq-GPCR activation specifically in peripheral GFAP+ satellite glial cells (within sympathetic ganglia) leads to increased norepinephrine release, beta-1 adrenergic receptor activation in the heart, and consequent acceleration of heart rate and increased left ventricular contraction, demonstrating a functional role for GFAP+ glia in regulating cardiovascular function.","method":"Transgenic mice expressing hM3Dq DREADD in GFAP+ cells; pharmacological activation with clozapine N-oxide; cardiovascular measurements; beta-blocker pharmacological dissection","journal":"JCI insight","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-type-specific chemogenetic manipulation with pharmacological dissection of downstream mechanism, single lab","pmids":["28138563"],"is_preprint":false},{"year":2018,"finding":"AxD-causing GFAP mutations in iPSC-derived human astrocytes cause GFAP aggregates, enlarged and perinuclearly localized endoplasmic reticulum and lysosomes, impaired extracellular ATP release, and attenuated calcium wave propagation, revealing that mutant GFAP disrupts intracellular vesicle regulation and astrocyte secretory function.","method":"iPSC-derived astrocytes from AxD patients with isogenic correction; RNA-seq; organelle morphology imaging; ATP release assay; calcium imaging","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — isogenic iPSC correction with multiple orthogonal methods (RNA-seq, organelle imaging, functional assays) in human cells; mechanistically rigorous","pmids":["30355500"],"is_preprint":false},{"year":2019,"finding":"GFAP and vimentin deficiency (GFAP-/-Vim-/- mice) results in decreased Notch signal-sending competence in astrocytes and altered expression of Notch signaling pathway genes (Dlk2, Notch1, Sox2), demonstrating that astrocyte intermediate filaments regulate Notch signaling capacity.","method":"Single-cell RT-qPCR on freshly isolated astrocytes from GFAP-/-Vim-/- and wild-type mice; hippocampal entorhinal cortex lesion model","journal":"Journal of neurochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockout with single-cell gene expression analysis, specific pathway readout, single lab","pmids":["26118771"],"is_preprint":false},{"year":2021,"finding":"GFAP is palmitoylated in vitro and in vivo at a unique site, cysteine-291; PPT1 is the depalmitoylating enzyme for GFAP; palmitoylated GFAP promotes astrocyte proliferation in vitro; in PPT1-knockin mice, hyperpalmitoylated GFAP drives astrogliosis and neurodegeneration, and mutating C291A attenuates astrogliosis and concurrent neurodegeneration.","method":"Palm-proteomics; in vitro palmitoylation assay; site-directed mutagenesis (C291A); PPT1-KI mouse model; astrocyte proliferation assays; immunohistology for astrogliosis markers","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro palmitoylation assay + site-directed mutagenesis + in vivo genetic mouse model with functional rescue; multiple orthogonal methods identifying unique modification site","pmids":["33753498"],"is_preprint":false},{"year":2019,"finding":"GFAP and vimentin double-knockout (GFAP-/-Vim-/-) mice show more pronounced memory extinction compared to wildtype mice in IntelliCage reversal learning, while other learning and memory measures are comparable, indicating a specific role for astrocyte intermediate filaments in hippocampal circuit reorganization.","method":"GFAP-/-Vim-/- mice; open field, object recognition, Morris water maze, trace fear conditioning, IntelliCage reversal learning behavioral tests","journal":"Biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockout with multiple behavioral tests; specific phenotype found in one paradigm, single lab","pmids":["31063456"],"is_preprint":false}],"current_model":"GFAP is the major type III intermediate filament protein of mature astrocytes that provides structural support and maintains cell shape; its expression is transcriptionally regulated by STAT3, NFI, SP1, NF-κB, MeCP2/SIN3A, and growth factors (TGF-β1, FGF-2) acting on defined promoter elements, and epigenetically controlled by histone acetylation; post-translationally, GFAP is palmitoylated at cysteine-291 (depalmitoylated by PPT1), with hyperpalmitoylation promoting astrocyte proliferation and astrogliosis; GFAP isoforms (GFAPα vs. GFAPδ) differ in filament network exchange dynamics and regulate focal adhesion size, cell morphology, and laminin-dependent motility; dominant missense mutations (e.g., R239C) cause Alexander disease through a gain-of-function mechanism involving filament network disorganization, decreased GFAP solubility, sequestration of chaperones αB-crystallin and HSP27 into Rosenthal fibers, JNK activation, impaired vesicle trafficking, and defective astrocyte ATP secretion and calcium signaling."},"narrative":{"mechanistic_narrative":"GFAP is the principal type III intermediate filament protein of differentiated CNS astrocytes, forming the glial cytoskeleton that defines and maintains astrocyte shape [PMID:2409105]. Its assembly into 10 nm filaments builds a dynamic network whose subunit exchange and organization are isoform-dependent: GFAPδ exchanges more slowly than GFAPα and shifting the isoform ratio reorganizes the network, alters focal adhesion size and cell morphology [PMID:27141937], and reprograms extracellular matrix engagement—changing plectin, laminin, and integrin levels to control adhesion and motility [PMID:24696300]. Beyond structural support, the GFAP/vimentin filament system regulates astrocyte signaling competence, tuning Notch signal-sending capacity [PMID:26118771] and contributing to hippocampal circuit plasticity underlying memory extinction [PMID:31063456]. GFAP expression is tightly controlled at a defined astrocyte-specific promoter [PMID:8120611, PMID:23832770] through a developmental switch in which repressive MeCP2/SIN3A occupancy gives way to STAT3 recruitment of CBP/p300 and activating histone modifications [PMID:21779366], and is further modulated by growth-factor and neurotransmitter inputs (TGF-β1 induction opposed by FGF-2; glutamate acting via mGluR2/3-TGF-β1-Smad signaling) [PMID:9537840, PMID:18419760]. Post-translationally, GFAP is palmitoylated at cysteine-291 and depalmitoylated by PPT1; hyperpalmitoylation drives astrocyte proliferation, astrogliosis, and neurodegeneration, which is attenuated by the C291A mutation [PMID:33753498]. Dominant de novo missense mutations in GFAP cause Alexander disease through a gain-of-function mechanism [PMID:12175861]: mutant (or excess) GFAP disorganizes the filament network and becomes detergent-insoluble [PMID:15840648], forming Rosenthal-fiber inclusions that sequester the chaperones αB-crystallin and HSP27, activate JNK stress signaling, and impair proteasome function [PMID:17498694, PMID:19146851], and in patient iPSC-derived astrocytes disrupt ER and lysosome morphology, ATP release, and calcium wave propagation [PMID:30355500].","teleology":[{"year":1985,"claim":"Established the founding identity of GFAP as the structural intermediate filament protein that builds the astrocyte cytoskeleton, defining the molecular basis of astrocyte shape.","evidence":"Biochemical and immunocytochemical characterization of glial filaments in CNS astrocytes","pmids":["2409105"],"confidence":"High","gaps":["Does not address regulation of expression","Does not address assembly dynamics or post-translational control"]},{"year":1989,"claim":"Showed GFAP expression is not constitutive but dynamically driven by extrinsic cues, including trophic and developmental inputs, rather than being a fixed cell marker.","evidence":"dbcAMP labeling of astrocyte cultures; sciatic nerve transection with mRNA readout; insulin-titrated organotypic cerebellar cultures; pulse-chase turnover kinetics","pmids":["2989328","2769798","1782546","2279327"],"confidence":"Medium","gaps":["Did not identify the promoter elements or transcription factors mediating these responses","Mechanism linking signal to GFAP transcription unresolved"]},{"year":1994,"claim":"Localized the regulatory logic of astrocyte-specific and injury-induced GFAP expression to a defined 5'-flanking promoter region, enabling dissection of its control elements.","evidence":"GFAP-promoter-lacZ transgenic mice with injury challenge","pmids":["8120611"],"confidence":"High","gaps":["Did not resolve which transcription factors bind which elements","Did not address chromatin-level regulation"]},{"year":2002,"claim":"Defined Alexander disease as a dominant gain-of-function disorder of GFAP, distinguishing toxic-intermediate accumulation from simple loss of filament function.","evidence":"Mutation sequencing across patient cohorts; epistatic comparison with GFAP-null mice","pmids":["12175861"],"confidence":"High","gaps":["Did not define the molecular nature of the toxic species","Did not link mutations to downstream cellular dysfunction"]},{"year":2005,"claim":"Resolved that disease mutations act on network organization and solubility rather than on filament polymerization, and connected progenitor signaling to GFAP+ cell identity.","evidence":"R239C transfection across cell lines with Triton-X-100 extraction and in vitro filament assembly; LIF/BMP treatment and transgenic BMP modulation of SVZ progenitors","pmids":["15840648","16314487"],"confidence":"High","gaps":["Did not identify the chaperone or stress pathways engaged by insoluble mutant GFAP","GFAP+ progenitor heterogeneity not molecularly resolved"]},{"year":2008,"claim":"Built a cellular pathogenic model linking mutant/excess GFAP accumulation to chaperone sequestration, JNK stress activation, proteasome impairment, and reduced astrocyte viability.","evidence":"Review synthesis plus primary chaperone co-localization and JNK assays; primary astrocytes from GFAP-overexpressing and R236H knock-in mice with proteasome and stress assays","pmids":["17498694","19146851"],"confidence":"Medium","gaps":["Causal order of chaperone sequestration vs JNK activation not established","Did not address organelle or secretory dysfunction"]},{"year":2008,"claim":"Mapped the transcriptional control of GFAP to discrete promoter elements and signaling inputs, establishing combinatorial astrocyte-specific and region-specific regulation.","evidence":"Transgenic promoter deletion/mutation analysis defining neuronal-silencer (C1.2) and region-specific (C1.1) elements and NFI/SP1/STAT3/NF-κB sites; reporter dissection of glutamate-mGluR2/3-TGF-β1-Smad activation","pmids":["18240313","18419760","23832770"],"confidence":"Medium","gaps":["Did not establish chromatin-state dynamics during differentiation","Quantitative contribution of each factor in vivo not fully resolved"]},{"year":2011,"claim":"Defined the epigenetic switch driving GFAP induction during astrocyte differentiation, converting a repressed promoter into an active one via chromatin remodeling.","evidence":"ChIP for MeCP2/SIN3A, STAT3, CBP/p300, Pol II and histone marks in differentiating NTera-2 cells; MeCP2 siRNA in developing rat brain; HDAC inhibitor and SR-protein studies","pmids":["21779366","24269336","25128567"],"confidence":"High","gaps":["Upstream trigger for SIN3A-MeCP2 departure not defined","Link between histone acetylation state and isoform splicing only partially resolved"]},{"year":2014,"claim":"Demonstrated that GFAP isoforms are functionally non-equivalent, with the GFAPα/GFAPδ ratio controlling network exchange dynamics, focal adhesions, ECM engagement, and motility.","evidence":"Isoform-specific shRNA silencing with adhesion/migration/integrin assays; FRAP of tagged GFAPα vs GFAPδ with morphology readouts","pmids":["24696300","27141937"],"confidence":"Medium","gaps":["Mechanism coupling filament exchange to focal-adhesion remodeling unresolved","Relevance of isoform balance in vivo not established"]},{"year":2018,"claim":"Showed in a human isogenic system that disease-mutant GFAP disrupts organelle morphology and astrocyte secretory function, extending pathogenesis beyond filament aggregation to ER/lysosome and ATP/calcium signaling defects.","evidence":"iPSC-derived AxD astrocytes with isogenic correction; RNA-seq, organelle imaging, ATP release and calcium imaging assays","pmids":["30355500"],"confidence":"High","gaps":["Mechanism linking filament aggregates to organelle enlargement not defined","Did not address therapeutic reversibility"]},{"year":2019,"claim":"Revealed signaling and behavioral roles of the astrocyte intermediate filament system beyond structure, including Notch signal-sending competence and hippocampal circuit plasticity.","evidence":"GFAP-/-Vim-/- mice with single-cell RT-qPCR and lesion model; behavioral battery including IntelliCage reversal learning","pmids":["26118771","31063456"],"confidence":"Medium","gaps":["Cannot separate GFAP-specific from vimentin contributions","Molecular link between filament loss and Notch competence unresolved"]},{"year":2021,"claim":"Identified a specific reversible lipid modification of GFAP and its erasing enzyme, establishing palmitoylation as a driver of astrocyte proliferation, astrogliosis, and neurodegeneration.","evidence":"Palm-proteomics and in vitro palmitoylation assay; C291A site-directed mutagenesis; PPT1-knockin mouse with functional rescue and astrogliosis markers","pmids":["33753498"],"confidence":"High","gaps":["Palmitoyltransferase that adds the modification not identified","Mechanistic link between palmitoylation and filament dynamics unresolved"]},{"year":2017,"claim":"Extended GFAP+ glial function to the periphery, showing GFAP+ satellite glia in sympathetic ganglia modulate cardiovascular output through neurotransmitter release.","evidence":"hM3Dq DREADD in GFAP+ cells with CNO activation, cardiovascular measurement, and beta-blocker dissection","pmids":["28138563"],"confidence":"Medium","gaps":["Did not establish a direct role for GFAP protein itself versus the GFAP+ cell type","Mechanism of neurotransmitter release control unresolved"]},{"year":null,"claim":"How the GFAP filament network mechanically and biochemically couples to organelle positioning, secretory function, and signaling competence—and how palmitoylation, isoform balance, and disease mutations converge on these outputs—remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model linking filament organization to organelle/secretory defects","Palmitoyltransferase for GFAP unidentified","Causal hierarchy among aggregation, chaperone sequestration, JNK, and organelle dysfunction in Alexander disease not established"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0005198","term_label":"structural molecule activity","supporting_discovery_ids":[0,10]},{"term_id":"GO:0008092","term_label":"cytoskeletal protein binding","supporting_discovery_ids":[20,21]}],"localization":[{"term_id":"GO:0005856","term_label":"cytoskeleton","supporting_discovery_ids":[0,10]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[10,15]}],"pathway":[{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[8,12,23]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[16,17]}],"complexes":["Rosenthal fibers"],"partners":["CRYAB","HSPB1","PPT1","VIM","PLEC"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P14136","full_name":"Glial fibrillary acidic protein","aliases":[],"length_aa":432,"mass_kda":49.9,"function":"GFAP, a class-III intermediate filament, is a cell-specific marker that, during the development of the central nervous system, distinguishes astrocytes from other glial cells","subcellular_location":"Cytoplasm","url":"https://www.uniprot.org/uniprotkb/P14136/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/GFAP","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/GFAP","total_profiled":1310},"omim":[{"mim_id":"621283","title":"COILED-COIL DOMAIN-CONTAINING PROTEIN 85C; CCDC85C","url":"https://www.omim.org/entry/621283"},{"mim_id":"620461","title":"ENCEPHALITIS, ACUTE, INFECTION-INDUCED, SUSCEPTIBILITY TO, 12; IIAE12","url":"https://www.omim.org/entry/620461"},{"mim_id":"620315","title":"LEUKOENCEPHALOPATHY WITH VANISHING WHITE MATTER 5; VWM5","url":"https://www.omim.org/entry/620315"},{"mim_id":"618037","title":"ZINC FINGER PROTEIN 536; ZNF536","url":"https://www.omim.org/entry/618037"},{"mim_id":"617894","title":"TRANSMEMBRANE PROTEIN 50B; TMEM50B","url":"https://www.omim.org/entry/617894"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Intermediate filaments","reliability":"Supported"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"brain","ntpm":15929.3}],"url":"https://www.proteinatlas.org/search/GFAP"},"hgnc":{"alias_symbol":["FLJ45472"],"prev_symbol":[]},"alphafold":{"accession":"P14136","domains":[{"cath_id":"-","chopping":"133-218_233-337","consensus_level":"medium","plddt":93.9655,"start":133,"end":337}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P14136","model_url":"https://alphafold.ebi.ac.uk/files/AF-P14136-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P14136-F1-predicted_aligned_error_v6.png","plddt_mean":80.0},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=GFAP","jax_strain_url":"https://www.jax.org/strain/search?query=GFAP"},"sequence":{"accession":"P14136","fasta_url":"https://rest.uniprot.org/uniprotkb/P14136.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P14136/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P14136"}},"corpus_meta":[{"pmid":"21219963","id":"PMC_21219963","title":"GFAP in health and disease.","date":"2011","source":"Progress in neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/21219963","citation_count":849,"is_preprint":false},{"pmid":"7952264","id":"PMC_7952264","title":"GFAP and astrogliosis.","date":"1994","source":"Brain pathology (Zurich, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/7952264","citation_count":738,"is_preprint":false},{"pmid":"25726916","id":"PMC_25726916","title":"Glial fibrillary acidic protein (GFAP) and the astrocyte intermediate filament system in diseases of the central nervous system.","date":"2015","source":"Current opinion in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/25726916","citation_count":699,"is_preprint":false},{"pmid":"2409105","id":"PMC_2409105","title":"Glial fibrillary acidic protein (GFAP): the major protein of glial intermediate filaments in differentiated astrocytes.","date":"1985","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/2409105","citation_count":675,"is_preprint":false},{"pmid":"8120611","id":"PMC_8120611","title":"GFAP promoter directs astrocyte-specific expression in transgenic mice.","date":"1994","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/8120611","citation_count":430,"is_preprint":false},{"pmid":"8247224","id":"PMC_8247224","title":"GFAP mRNA increases with age in rat and human brain.","date":"1993","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/8247224","citation_count":348,"is_preprint":false},{"pmid":"18240313","id":"PMC_18240313","title":"GFAP promoter elements required for region-specific and astrocyte-specific expression.","date":"2008","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/18240313","citation_count":321,"is_preprint":false},{"pmid":"16765104","id":"PMC_16765104","title":"GFAP transgenic zebrafish.","date":"2006","source":"Gene expression patterns : GEP","url":"https://pubmed.ncbi.nlm.nih.gov/16765104","citation_count":302,"is_preprint":false},{"pmid":"16314487","id":"PMC_16314487","title":"LIF and BMP signaling generate separate and discrete types of GFAP-expressing cells.","date":"2005","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/16314487","citation_count":223,"is_preprint":false},{"pmid":"34572572","id":"PMC_34572572","title":"Beyond the GFAP-Astrocyte Protein Markers in the Brain.","date":"2021","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/34572572","citation_count":222,"is_preprint":false},{"pmid":"21917775","id":"PMC_21917775","title":"GFAP mutations, age at onset, and clinical subtypes in Alexander disease.","date":"2011","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/21917775","citation_count":204,"is_preprint":false},{"pmid":"17498694","id":"PMC_17498694","title":"GFAP and its role in Alexander disease.","date":"2007","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/17498694","citation_count":156,"is_preprint":false},{"pmid":"24749759","id":"PMC_24749759","title":"Enteric GFAP expression and phosphorylation in Parkinson's disease.","date":"2014","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24749759","citation_count":152,"is_preprint":false},{"pmid":"10412574","id":"PMC_10412574","title":"Glial fibrillary acidic protein (GFAP): modulation by growth factors and its implication in astrocyte differentiation.","date":"1999","source":"Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas","url":"https://pubmed.ncbi.nlm.nih.gov/10412574","citation_count":152,"is_preprint":false},{"pmid":"7952266","id":"PMC_7952266","title":"Structure and transcriptional regulation of the GFAP gene.","date":"1994","source":"Brain pathology (Zurich, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/7952266","citation_count":138,"is_preprint":false},{"pmid":"12931206","id":"PMC_12931206","title":"Neuronal expression of GFAP in patients with Alzheimer pathology and identification of novel GFAP splice forms.","date":"2003","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/12931206","citation_count":133,"is_preprint":false},{"pmid":"30991306","id":"PMC_30991306","title":"Clinical characteristics of autoimmune GFAP astrocytopathy.","date":"2019","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/30991306","citation_count":132,"is_preprint":false},{"pmid":"12928288","id":"PMC_12928288","title":"Differential expression of GFAP in early v late AMD: a quantitative analysis.","date":"2003","source":"The British journal of ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/12928288","citation_count":132,"is_preprint":false},{"pmid":"29196434","id":"PMC_29196434","title":"Type III Intermediate Filaments Desmin, Glial Fibrillary Acidic Protein (GFAP), Vimentin, and Peripherin.","date":"2017","source":"Cold Spring Harbor perspectives in biology","url":"https://pubmed.ncbi.nlm.nih.gov/29196434","citation_count":111,"is_preprint":false},{"pmid":"35656116","id":"PMC_35656116","title":"Blocking C3d+/GFAP+ A1 Astrocyte Conversion with Semaglutide Attenuates Blood-Brain Barrier Disruption in Mice after Ischemic Stroke.","date":"2022","source":"Aging and disease","url":"https://pubmed.ncbi.nlm.nih.gov/35656116","citation_count":107,"is_preprint":false},{"pmid":"12175861","id":"PMC_12175861","title":"GFAP mutations in Alexander disease.","date":"2002","source":"International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/12175861","citation_count":106,"is_preprint":false},{"pmid":"35252538","id":"PMC_35252538","title":"Association of plasma glial fibrillary acidic protein (GFAP) with neuroimaging of Alzheimer's disease and vascular pathology.","date":"2022","source":"Alzheimer's & dementia (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/35252538","citation_count":106,"is_preprint":false},{"pmid":"15662842","id":"PMC_15662842","title":"Expression specificity of GFAP transgenes.","date":"2004","source":"Neurochemical research","url":"https://pubmed.ncbi.nlm.nih.gov/15662842","citation_count":101,"is_preprint":false},{"pmid":"33601918","id":"PMC_33601918","title":"Regulation of GFAP Expression.","date":"2021","source":"ASN neuro","url":"https://pubmed.ncbi.nlm.nih.gov/33601918","citation_count":100,"is_preprint":false},{"pmid":"35002283","id":"PMC_35002283","title":"Glial Fibrillary Acidic Protein (GFAP): Neuroinflammation Biomarker in Acute Ischemic Stroke.","date":"2021","source":"Journal of inflammation research","url":"https://pubmed.ncbi.nlm.nih.gov/35002283","citation_count":99,"is_preprint":false},{"pmid":"32811163","id":"PMC_32811163","title":"GFAP at 50.","date":"2020","source":"ASN neuro","url":"https://pubmed.ncbi.nlm.nih.gov/32811163","citation_count":96,"is_preprint":false},{"pmid":"27074724","id":"PMC_27074724","title":"Assessment of Serum UCH-L1 and GFAP in Acute Stroke Patients.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27074724","citation_count":92,"is_preprint":false},{"pmid":"9537840","id":"PMC_9537840","title":"Regulation of astrocyte GFAP expression by TGF-beta1 and FGF-2.","date":"1998","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/9537840","citation_count":91,"is_preprint":false},{"pmid":"15331155","id":"PMC_15331155","title":"Non-invasive imaging of GFAP expression after neuronal damage in mice.","date":"2004","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/15331155","citation_count":91,"is_preprint":false},{"pmid":"28962102","id":"PMC_28962102","title":"GFAP expression in injured astrocytes in rats.","date":"2017","source":"Experimental and therapeutic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28962102","citation_count":88,"is_preprint":false},{"pmid":"32804092","id":"PMC_32804092","title":"Serum Glial Fibrillary Acidic Protein (GFAP) Is a Marker of Disease Severity in Frontotemporal Lobar Degeneration.","date":"2020","source":"Journal of Alzheimer's disease : JAD","url":"https://pubmed.ncbi.nlm.nih.gov/32804092","citation_count":88,"is_preprint":false},{"pmid":"2989328","id":"PMC_2989328","title":"Regulation of glial fibrillary acidic protein (GFAP) expression in CNS development and in pathological states.","date":"1985","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/2989328","citation_count":86,"is_preprint":false},{"pmid":"2449946","id":"PMC_2449946","title":"Ependymal and choroid plexus tumors. Cytokeratin and GFAP expression.","date":"1988","source":"Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/2449946","citation_count":80,"is_preprint":false},{"pmid":"35204724","id":"PMC_35204724","title":"Neuroinflammation Is Associated with GFAP and sTREM2 Levels in Multiple Sclerosis.","date":"2022","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/35204724","citation_count":74,"is_preprint":false},{"pmid":"9591779","id":"PMC_9591779","title":"Correlation of B-FABP and GFAP expression in malignant glioma.","date":"1998","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/9591779","citation_count":73,"is_preprint":false},{"pmid":"12761871","id":"PMC_12761871","title":"GFAP: functional implications gleaned from studies of genetically engineered mice.","date":"2003","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/12761871","citation_count":73,"is_preprint":false},{"pmid":"6543600","id":"PMC_6543600","title":"Glial fibrillary acidic protein (GFAP) immunoreactivity in peripheral nerve sheath tumors.","date":"1984","source":"Ultrastructural pathology","url":"https://pubmed.ncbi.nlm.nih.gov/6543600","citation_count":70,"is_preprint":false},{"pmid":"30667110","id":"PMC_30667110","title":"Importance of GFAP isoform-specific analyses in astrocytoma.","date":"2019","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/30667110","citation_count":68,"is_preprint":false},{"pmid":"15840648","id":"PMC_15840648","title":"Alexander-disease mutation of GFAP causes filament disorganization and decreased solubility of GFAP.","date":"2005","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/15840648","citation_count":66,"is_preprint":false},{"pmid":"30951262","id":"PMC_30951262","title":"Enteric Glia: S100, GFAP, and Beyond.","date":"2019","source":"Anatomical record (Hoboken, N.J. : 2007)","url":"https://pubmed.ncbi.nlm.nih.gov/30951262","citation_count":65,"is_preprint":false},{"pmid":"10384875","id":"PMC_10384875","title":"Neurons induce GFAP gene promoter of cultured astrocytes from transgenic mice.","date":"1999","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/10384875","citation_count":63,"is_preprint":false},{"pmid":"8954847","id":"PMC_8954847","title":"GFAP Transgenic Mice.","date":"1996","source":"Methods (San Diego, Calif.)","url":"https://pubmed.ncbi.nlm.nih.gov/8954847","citation_count":61,"is_preprint":false},{"pmid":"1723659","id":"PMC_1723659","title":"Developmental expression of the glial fibrillary acidic protein (GFAP) gene in the mouse retina.","date":"1991","source":"Cellular and molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/1723659","citation_count":61,"is_preprint":false},{"pmid":"8738264","id":"PMC_8738264","title":"Repeated seizures increase GFAP and vimentin in the hippocampus.","date":"1996","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/8738264","citation_count":60,"is_preprint":false},{"pmid":"19899109","id":"PMC_19899109","title":"Purity, cell viability, expression of GFAP and bystin in astrocytes cultured by different procedures.","date":"2010","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19899109","citation_count":58,"is_preprint":false},{"pmid":"15634232","id":"PMC_15634232","title":"Olig2 expression, GFAP, p53 and 1p loss analysis contribute to glioma subclassification.","date":"2005","source":"Neuropathology and applied neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/15634232","citation_count":57,"is_preprint":false},{"pmid":"28802830","id":"PMC_28802830","title":"GFAP in early multiple sclerosis: A biomarker for inflammation.","date":"2017","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/28802830","citation_count":57,"is_preprint":false},{"pmid":"16482522","id":"PMC_16482522","title":"Astrocyte heterogeneity revealed by expression of a GFAP-LacZ transgene.","date":"2006","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/16482522","citation_count":57,"is_preprint":false},{"pmid":"38216970","id":"PMC_38216970","title":"Prediction of clinical progression in nervous system diseases: plasma glial fibrillary acidic protein (GFAP).","date":"2024","source":"European journal of medical research","url":"https://pubmed.ncbi.nlm.nih.gov/38216970","citation_count":55,"is_preprint":false},{"pmid":"31063456","id":"PMC_31063456","title":"The role of GFAP and vimentin in learning and memory.","date":"2019","source":"Biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31063456","citation_count":55,"is_preprint":false},{"pmid":"30355500","id":"PMC_30355500","title":"Mutations in GFAP Disrupt the Distribution and Function of Organelles in Human Astrocytes.","date":"2018","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/30355500","citation_count":55,"is_preprint":false},{"pmid":"2769798","id":"PMC_2769798","title":"Neuronal modulation of Schwann cell glial fibrillary acidic protein (GFAP).","date":"1989","source":"Journal of neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/2769798","citation_count":54,"is_preprint":false},{"pmid":"18419760","id":"PMC_18419760","title":"Glutamate activates GFAP gene promoter from cultured astrocytes through TGF-beta1 pathways.","date":"2008","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18419760","citation_count":54,"is_preprint":false},{"pmid":"25128567","id":"PMC_25128567","title":"Histone acetylation in astrocytes suppresses GFAP and stimulates a reorganization of the intermediate filament network.","date":"2014","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/25128567","citation_count":54,"is_preprint":false},{"pmid":"34021122","id":"PMC_34021122","title":"Increased GFAP concentrations in the cerebrospinal fluid of patients with unipolar depression.","date":"2021","source":"Translational psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/34021122","citation_count":53,"is_preprint":false},{"pmid":"12882814","id":"PMC_12882814","title":"GFAP promoter drives Müller cell-specific expression in transgenic mice.","date":"2003","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/12882814","citation_count":50,"is_preprint":false},{"pmid":"16205370","id":"PMC_16205370","title":"Expression of MBP, PLP, MAG, CNP, and GFAP in the Human Alcoholic Brain.","date":"2005","source":"Alcoholism, clinical and experimental research","url":"https://pubmed.ncbi.nlm.nih.gov/16205370","citation_count":50,"is_preprint":false},{"pmid":"21779366","id":"PMC_21779366","title":"Interplay between SIN3A and STAT3 mediates chromatin conformational changes and GFAP expression during cellular differentiation.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21779366","citation_count":50,"is_preprint":false},{"pmid":"1782546","id":"PMC_1782546","title":"Insulin influences astroglial morphology and glial fibrillary acidic protein (GFAP) expression in organotypic cultures.","date":"1991","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/1782546","citation_count":50,"is_preprint":false},{"pmid":"33753498","id":"PMC_33753498","title":"GFAP hyperpalmitoylation exacerbates astrogliosis and neurodegenerative pathology in PPT1-deficient mice.","date":"2021","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/33753498","citation_count":47,"is_preprint":false},{"pmid":"20479526","id":"PMC_20479526","title":"Vimentin and GFAP responses in astrocytes after contusion trauma to the murine brain.","date":"2010","source":"Restorative neurology and neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/20479526","citation_count":47,"is_preprint":false},{"pmid":"27141937","id":"PMC_27141937","title":"GFAP isoforms control intermediate filament network dynamics, cell morphology, and focal adhesions.","date":"2016","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/27141937","citation_count":44,"is_preprint":false},{"pmid":"2200639","id":"PMC_2200639","title":"Müller cell GFAP expression exhibits gradient from focus of photoreceptor light damage.","date":"1990","source":"Current eye research","url":"https://pubmed.ncbi.nlm.nih.gov/2200639","citation_count":44,"is_preprint":false},{"pmid":"17720962","id":"PMC_17720962","title":"Glial fibrillary acidic protein (GFAP) and anti-GFAP autoantibody in canine necrotising meningoencephalitis.","date":"2007","source":"The Veterinary record","url":"https://pubmed.ncbi.nlm.nih.gov/17720962","citation_count":43,"is_preprint":false},{"pmid":"34114049","id":"PMC_34114049","title":"GFAP positivity in neurons following traumatic brain injuries.","date":"2021","source":"International journal of legal medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34114049","citation_count":43,"is_preprint":false},{"pmid":"19146851","id":"PMC_19146851","title":"Properties of astrocytes cultured from GFAP over-expressing and GFAP mutant mice.","date":"2008","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/19146851","citation_count":42,"is_preprint":false},{"pmid":"7890332","id":"PMC_7890332","title":"Normal and pathological expression of GFAP promoter elements in transgenic mice.","date":"1994","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/7890332","citation_count":40,"is_preprint":false},{"pmid":"4034433","id":"PMC_4034433","title":"GFAP in brain tumor diagnosis: possibilities and limitations.","date":"1985","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/4034433","citation_count":40,"is_preprint":false},{"pmid":"20538881","id":"PMC_20538881","title":"Drug screening to identify suppressors of GFAP expression.","date":"2010","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20538881","citation_count":39,"is_preprint":false},{"pmid":"36878332","id":"PMC_36878332","title":"Hippocampal GFAP-positive astrocyte responses to amyloid and tau pathologies.","date":"2023","source":"Brain, behavior, and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/36878332","citation_count":37,"is_preprint":false},{"pmid":"2279327","id":"PMC_2279327","title":"GFAP turnover during astroglial proliferation and differentiation.","date":"1990","source":"Brain research. Developmental brain research","url":"https://pubmed.ncbi.nlm.nih.gov/2279327","citation_count":37,"is_preprint":false},{"pmid":"23832770","id":"PMC_23832770","title":"Transgenic analysis of GFAP promoter elements.","date":"2013","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/23832770","citation_count":37,"is_preprint":false},{"pmid":"28138563","id":"PMC_28138563","title":"Ganglionic GFAP  glial Gq-GPCR signaling enhances heart functions in vivo.","date":"2017","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/28138563","citation_count":37,"is_preprint":false},{"pmid":"26478912","id":"PMC_26478912","title":"CSF and Blood Levels of GFAP in Alexander Disease.","date":"2015","source":"eNeuro","url":"https://pubmed.ncbi.nlm.nih.gov/26478912","citation_count":36,"is_preprint":false},{"pmid":"26118771","id":"PMC_26118771","title":"Heterogeneity of Notch signaling in astrocytes and the effects of GFAP and vimentin deficiency.","date":"2015","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26118771","citation_count":35,"is_preprint":false},{"pmid":"24269336","id":"PMC_24269336","title":"MeCP2 regulates GFAP expression within the developing brain.","date":"2013","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/24269336","citation_count":33,"is_preprint":false},{"pmid":"36067832","id":"PMC_36067832","title":"Serum GFAP - reference interval and preanalytical properties in Danish adults.","date":"2022","source":"Clinical chemistry and laboratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36067832","citation_count":32,"is_preprint":false},{"pmid":"33047897","id":"PMC_33047897","title":"Plasma NfL and GFAP as biomarkers of spinal cord degeneration in adrenoleukodystrophy.","date":"2020","source":"Annals of clinical and translational neurology","url":"https://pubmed.ncbi.nlm.nih.gov/33047897","citation_count":32,"is_preprint":false},{"pmid":"39289040","id":"PMC_39289040","title":"The GFAP proteoform puzzle: How to advance GFAP as a fluid biomarker in neurological diseases.","date":"2024","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/39289040","citation_count":31,"is_preprint":false},{"pmid":"24696300","id":"PMC_24696300","title":"Silencing GFAP isoforms in astrocytoma cells disturbs laminin-dependent motility and cell adhesion.","date":"2014","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/24696300","citation_count":31,"is_preprint":false},{"pmid":"3705189","id":"PMC_3705189","title":"Anaplasia and heterogeneity of GFAP expression in gliomas.","date":"1986","source":"Tumori","url":"https://pubmed.ncbi.nlm.nih.gov/3705189","citation_count":30,"is_preprint":false},{"pmid":"11923020","id":"PMC_11923020","title":"GFAP expression withdraws--a trend of glial evolution?","date":"2002","source":"Brain research bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/11923020","citation_count":30,"is_preprint":false},{"pmid":"32217788","id":"PMC_32217788","title":"CSF levels of glutamine synthetase and GFAP to explore astrocytic damage in seronegative NMOSD.","date":"2020","source":"Journal of neurology, neurosurgery, and psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/32217788","citation_count":30,"is_preprint":false},{"pmid":"25178519","id":"PMC_25178519","title":"Immunohistochemical analysis of GFAP-δ and nestin in cerebral astrocytomas.","date":"2014","source":"Brain tumor pathology","url":"https://pubmed.ncbi.nlm.nih.gov/25178519","citation_count":29,"is_preprint":false},{"pmid":"22410258","id":"PMC_22410258","title":"Serum GFAP levels in optic neuropathies.","date":"2012","source":"Journal of the neurological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/22410258","citation_count":29,"is_preprint":false},{"pmid":"37000892","id":"PMC_37000892","title":"Plasma GFAP associates with secondary Alzheimer's pathology in Lewy body disease.","date":"2023","source":"Annals of clinical and translational neurology","url":"https://pubmed.ncbi.nlm.nih.gov/37000892","citation_count":28,"is_preprint":false},{"pmid":"33421075","id":"PMC_33421075","title":"Expression of GFAP and Tau Following Blast Exposure in the Cerebral Cortex of Ferrets.","date":"2021","source":"Journal of neuropathology and experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/33421075","citation_count":28,"is_preprint":false},{"pmid":"22301378","id":"PMC_22301378","title":"Quantitative analysis of GFAP- and S100 protein-immunopositive astrocytes to investigate the severity of traumatic brain injury.","date":"2012","source":"Legal medicine (Tokyo, Japan)","url":"https://pubmed.ncbi.nlm.nih.gov/22301378","citation_count":28,"is_preprint":false},{"pmid":"35673702","id":"PMC_35673702","title":"GFAP Alternative Splicing and the Relevance for Disease - A Focus on Diffuse Gliomas.","date":"2022","source":"ASN neuro","url":"https://pubmed.ncbi.nlm.nih.gov/35673702","citation_count":27,"is_preprint":false},{"pmid":"1649261","id":"PMC_1649261","title":"Schwann cell GFAP expression increases in axonal neuropathies.","date":"1991","source":"Journal of the neurological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/1649261","citation_count":26,"is_preprint":false},{"pmid":"26090233","id":"PMC_26090233","title":"Striatal Injury with 6-OHDA Transiently Increases Cerebrospinal GFAP and S100B.","date":"2015","source":"Neural plasticity","url":"https://pubmed.ncbi.nlm.nih.gov/26090233","citation_count":26,"is_preprint":false},{"pmid":"27579183","id":"PMC_27579183","title":"Anorexia Reduces GFAP+ Cell Density in the Rat Hippocampus.","date":"2016","source":"Neural plasticity","url":"https://pubmed.ncbi.nlm.nih.gov/27579183","citation_count":25,"is_preprint":false},{"pmid":"38401182","id":"PMC_38401182","title":"GFAP-isoforms in the nervous system: Understanding the need for diversity.","date":"2024","source":"Current opinion in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/38401182","citation_count":24,"is_preprint":false},{"pmid":"23840007","id":"PMC_23840007","title":"GFAP expression and social deficits in transgenic mice overexpressing human sAPPα.","date":"2013","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/23840007","citation_count":24,"is_preprint":false},{"pmid":"21987397","id":"PMC_21987397","title":"Archetypal and new families with Alexander disease and novel mutations in GFAP.","date":"2011","source":"Archives of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/21987397","citation_count":24,"is_preprint":false},{"pmid":"1319273","id":"PMC_1319273","title":"Glial fibrillary acidic protein (GFAP) expression and nucleolar organizer regions (NORs) in human gliomas.","date":"1992","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/1319273","citation_count":24,"is_preprint":false},{"pmid":"31838996","id":"PMC_31838996","title":"Refining the concept of GFAP toxicity in Alexander disease.","date":"2019","source":"Journal of neurodevelopmental disorders","url":"https://pubmed.ncbi.nlm.nih.gov/31838996","citation_count":23,"is_preprint":false},{"pmid":"26953813","id":"PMC_26953813","title":"Asymmetric Distribution of GFAP in Glioma Multipotent Cells.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26953813","citation_count":23,"is_preprint":false},{"pmid":"38805359","id":"PMC_38805359","title":"Serum NfL and GFAP as biomarkers of progressive neurodegeneration in TBI.","date":"2024","source":"Alzheimer's & dementia : the journal of the Alzheimer's Association","url":"https://pubmed.ncbi.nlm.nih.gov/38805359","citation_count":21,"is_preprint":false},{"pmid":"37187609","id":"PMC_37187609","title":"Striatal spatial heterogeneity, clustering, and white matter association of GFAP+ astrocytes in a mouse model of Huntington's disease.","date":"2023","source":"Frontiers in cellular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/37187609","citation_count":21,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":46153,"output_tokens":6610,"usd":0.118804,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":15797,"output_tokens":4444,"usd":0.095043,"stage2_stop_reason":"end_turn"},"total_usd":0.213847,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1985,\n      \"finding\": \"GFAP is the major protein constituent of glial intermediate filaments in differentiated fibrous and protoplasmic astrocytes of the CNS, functioning as a cytoskeletal component that defines and maintains the shape of astrocytes.\",\n      \"method\": \"Biochemical characterization, immunochemical and immunocytochemical studies\",\n      \"journal\": \"Journal of neuroimmunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — extensively replicated across hundreds of labs using multiple orthogonal methods over decades; foundational characterization of GFAP as the structural IF protein of astrocytes\",\n      \"pmids\": [\"2409105\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1985,\n      \"finding\": \"Dibutyryl cyclic AMP (dbcAMP) increases GFAP synthesis in cultured astrocytes, as demonstrated by radioactive methionine labeling showing increased GFAP and vimentin synthesis within 48 h of exposure.\",\n      \"method\": \"Radioactive metabolic labeling of primary astrocyte cultures treated with dbcAMP\",\n      \"journal\": \"Journal of neuroimmunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct biochemical labeling experiment in primary cultures, single lab but clear mechanistic readout\",\n      \"pmids\": [\"2989328\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1989,\n      \"finding\": \"Schwann cell expression of GFAP is developmentally regulated and requires continued trophic input from small axons; sciatic nerve transection causes marked reduction in GFAP mRNA in the distal stump, demonstrating axon-dependent regulation of GFAP in peripheral glia.\",\n      \"method\": \"Northern blot of sciatic nerve RNA after nerve transection; immunohistology of teased nerve fascicles\",\n      \"journal\": \"Journal of neuroscience research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct loss-of-function (transection) with defined molecular readout (mRNA reduction), single lab\",\n      \"pmids\": [\"2769798\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"GFAP turnover in cultured astrocytes is biphasic, with a fast-decaying pool (half-life ~16–18 h) and a stable pool (half-life ~5–6 days); the stable pool increases proportionally as astrocytes mature, reflecting dynamic regulation of GFAP during differentiation.\",\n      \"method\": \"Pulse-chase radiolabeling of primary astroglial cultures at different developmental stages\",\n      \"journal\": \"Brain research. Developmental brain research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — quantitative kinetic pulse-chase experiment in primary cultures, single lab\",\n      \"pmids\": [\"2279327\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"Insulin-related peptides regulate GFAP expression and astrocyte morphology in organotypic cerebellar cultures; high insulin levels increase GFAP mRNA and protein with enrichment of radial glial morphology, while low insulin levels produce undifferentiated epithelioid cells with minimal GFAP expression.\",\n      \"method\": \"Organotypic cultures of E17 mouse cerebellum with varying insulin concentrations; non-isotopic in situ hybridization for GFAP mRNA; GFAP immunoreactivity\",\n      \"journal\": \"Brain research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two orthogonal methods (ISH + immunostaining) in a defined culture system, single lab\",\n      \"pmids\": [\"1782546\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"A 2.2 kb 5'-flanking sequence of the human GFAP gene is sufficient to direct astrocyte-specific expression in transgenic mice and recapitulates injury-induced upregulation of GFAP, demonstrating that key transcriptional regulatory elements reside in this promoter region.\",\n      \"method\": \"Transgenic mice carrying GFAP-promoter-lacZ reporter; histochemical staining after CNS injury\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo transgenic reporter system replicated across multiple labs; key promoter element functionally validated\",\n      \"pmids\": [\"8120611\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"TGF-β1 significantly increases GFAP mRNA and protein in astrocytes, while FGF-2 significantly decreases GFAP mRNA and protein and inhibits TGF-β1-mediated increases; FGF-2 effects are blocked by an FGFR tyrosine kinase inhibitor, indicating receptor-mediated signaling.\",\n      \"method\": \"Primary astrocyte cultures treated with TGF-β1 and FGF-2; Western blot and mRNA analysis; pharmacological inhibition with 5'-methylthioadenosine and cycloheximide\",\n      \"journal\": \"Glia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple pharmacological manipulations with mRNA and protein readouts in primary cultures, single lab\",\n      \"pmids\": [\"9537840\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Neurons secrete brain-region-specific soluble factors that activate the GFAP gene promoter in astrocytes, inducing glial differentiation and cell cycle arrest, as demonstrated using transgenic astrocytes carrying a GFAP promoter-β-galactosidase reporter.\",\n      \"method\": \"Co-culture of neurons and transgenic astrocytes (GFAP-promoter-β-gal reporter mice); conditioned medium experiments; cell cycle analysis\",\n      \"journal\": \"Glia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter gene system with conditioned medium controls, defined cellular phenotype, single lab\",\n      \"pmids\": [\"10384875\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"GFAP coding mutations in Alexander disease are heterozygous missense mutations found in the 1A, 2A, and 2B rod domains and the tail region; all are de novo dominant mutations, and the disease likely results from a dominant gain-of-function (partial block of filament assembly leading to accumulation of a toxic intermediate) rather than dominant loss-of-function, since GFAP null mice do not display Alexander disease symptoms.\",\n      \"method\": \"Sequencing of GFAP coding regions from Alexander disease patients; genetic analysis of multiple disease cases; comparison with GFAP null mouse phenotype\",\n      \"journal\": \"International journal of developmental neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — replicated across multiple labs; null mouse phenotype provides epistatic evidence; gain-of-function mechanism supported by multiple independent patient analyses\",\n      \"pmids\": [\"12175861\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"GFAP contains novel splice forms (Δ135 nt, Δexon 6, Δ164 nt) expressed as out-of-frame variants in neurons (pyramidal neurons of hippocampus), particularly associated with Alzheimer's disease pathology and Down syndrome, demonstrating cell-type-specific alternative splicing of GFAP.\",\n      \"method\": \"RT-PCR identification of novel splice variants; immunohistochemistry on human hippocampal tissue from AD, Down syndrome, and control cases\",\n      \"journal\": \"Molecular psychiatry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two orthogonal methods (molecular cloning + immunohistochemistry), single lab\",\n      \"pmids\": [\"12931206\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"The Alexander disease-causing R239C mutation in GFAP causes filament disorganization and decreased solubility: in SW13Vim(-) cells R239C GFAP forms diffuse/irregular rather than filamentous networks, and Triton-X-100 extraction shows R239C GFAP is more resistant to solubilization. Both wild-type and R239C GFAP assemble into 10 nm filaments in vitro with similar morphology, indicating the mutation affects network organization and solubility rather than filament formation per se.\",\n      \"method\": \"Transient transfection of R239C GFAP into SW13Vim(-) cells, primary rat astrocytes, Cos-7 cells; Triton-X-100 extraction; in vitro filament assembly assay\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution of filament assembly combined with cell-based solubility assay and mutagenesis; multiple cell systems tested in one study\",\n      \"pmids\": [\"15840648\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"LIF signaling generates GFAP+ cells that retain progenitor characteristics (remain in cell cycle, self-renew, enhanced neurogenesis), while BMP signaling generates GFAP+ cells that are stellate, exit cell cycle, and lack progenitor traits. In vivo, transgenic BMP4 overexpression increases GFAP+ astrocytes but depletes the GFAP+ progenitor pool, while BMP inhibition has the opposite effect.\",\n      \"method\": \"Treatment of cultured embryonic SVZ progenitors with LIF or BMP; transgenic mice overexpressing BMP4 or inhibitor of BMP signaling; cell cycle analysis; immunostaining\",\n      \"journal\": \"Development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vitro and in vivo experiments with genetic epistasis (transgenic gain and loss of BMP signaling) converging on same conclusion\",\n      \"pmids\": [\"16314487\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"GFAP mutations in Alexander disease cause: (i) GFAP accumulation and Rosenthal fiber formation, (ii) sequestration of protein chaperones αB-crystallin and HSP27 into Rosenthal fibers, and (iii) activation of JNK and the stress response, collectively driving disease pathogenesis.\",\n      \"method\": \"Review synthesizing data from patient tissue, cell transfection studies, and mouse models; immunostaining for chaperones in Rosenthal fibers; JNK activation assays\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — synthesizes experimental data from multiple studies; direct co-localization and kinase activation demonstrated, but review article compiles rather than presents primary data\",\n      \"pmids\": [\"17498694\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Glutamate activates the GFAP gene promoter in astrocytes through metabotropic glutamate receptors (mGluR2/3), triggering TGF-β1 secretion, which activates Smad transcription factor nuclear translocation; MAPK and PI3K pathways are also required for TGF-β1-induced GFAP gene activation, suggesting cooperation between canonical (Smad) and non-canonical TGF-β pathways.\",\n      \"method\": \"Transgenic astrocytes with GFAP-promoter-β-gal reporter; neutralizing antibodies against TGF-β; mGluR antagonist MCPG; MAPK inhibitor PD98059; PI3K inhibitor LY294002; Smad-2 phosphorylation assay\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple pharmacological inhibitors with reporter readout; mechanistic pathway defined, single lab\",\n      \"pmids\": [\"18419760\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"The human GFAP promoter contains specific DNA elements required for astrocyte specificity and region-specific expression: a 45 bp sequence (bp -1443 to -1399, C1.2) is required for silencing GFAP expression in neurons, and a 55 bp segment (bp -1488 to -1434, C1.1) contains region-specific elements.\",\n      \"method\": \"Transgenic mice carrying GFAP promoter deletion constructs linked to lacZ reporter; brain region analysis of reporter expression\",\n      \"journal\": \"Glia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo transgenic deletion analysis identifies functional promoter elements; single lab\",\n      \"pmids\": [\"18240313\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Mutant GFAP (Alexander disease), as well as excess wild-type GFAP, promotes formation of cytoplasmic inclusions, disrupts the cytoskeleton, decreases cell proliferation, increases cell death, reduces proteasomal function, and compromises astrocyte stress resistance in primary astrocyte cultures.\",\n      \"method\": \"Primary astrocyte cultures from GFAP over-expressing transgenic mice and GFAP knock-in (R236H) mice; immunostaining; proteasome activity assays; cell proliferation and death assays; stress challenge\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two genetic mouse models with multiple cellular readouts; single lab\",\n      \"pmids\": [\"19146851\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"SIN3A coupled with MeCP2 binds to the GFAP promoter to repress GFAP transcription; upon astrocyte differentiation, SIN3A-MeCP2 departs and activated STAT3 binds to the promoter and exon 1, recruiting CBP/p300 to exon 1, leading to H3K9 and H3K14 acetylation and H3K4 trimethylation that activate GFAP gene transcription.\",\n      \"method\": \"ChIP assays for SIN3A, MeCP2, STAT3, CBP/p300, RNA Pol II, histone marks; NTera-2 cell differentiation into astrocyte-like lineage\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — chromatin immunoprecipitation with multiple histone mark readouts and transcription factor occupancy, mechanistically well-defined, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"21779366\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"GFAP promoter activity is regulated by NFI, SP1, STAT3, and NF-κB binding sites (but not the consensus AP-1 site) within the B region (bp -1612 to -1489), with each subregion contributing cooperatively to transcriptional strength and astrocyte specificity.\",\n      \"method\": \"Transgenic mice with block mutations and specific transcription factor binding site mutations in GFAP promoter-reporter constructs; analysis of expression level, brain region pattern, and astrocyte specificity\",\n      \"journal\": \"Glia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo transgenic mutational analysis of promoter elements, single lab\",\n      \"pmids\": [\"23832770\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"MeCP2 binds to methylated regions of the GFAP promoter and represses GFAP expression; siRNA knockdown of MeCP2 in the developing female rat amygdala and hypothalamus specifically increases GFAP mRNA and protein without altering other astrocyte markers (S100β, vimentin).\",\n      \"method\": \"MeCP2 siRNA infusion into rat brain; RT-PCR and Western blot for GFAP, S100β, and vimentin; sex-specific analysis\",\n      \"journal\": \"Brain research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo RNAi with specificity controls (S100β, vimentin unchanged), single lab\",\n      \"pmids\": [\"24269336\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"HDAC inhibition (trichostatin A or sodium butyrate) reduces GFAP expression in human astrocytes and astrocytoma cells and increases the GFAPδ:GFAPα ratio, with the alternative isoform expression being dependent on SR protein splicing factors. HDAC inhibition also induces aggregation of the GFAP network resembling Alexander disease pathology.\",\n      \"method\": \"Primary human astrocytes and astrocytoma cells treated with HDAC inhibitors; qRT-PCR for isoforms; immunostaining for network organization; siRNA knockdown of SR proteins\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple pharmacological agents plus siRNA knockdown; two orthogonal methods (mRNA and protein), single lab\",\n      \"pmids\": [\"25128567\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Shifting the GFAP isoform ratio toward GFAPδ (by shRNA silencing of GFAPα) decreases plectin expression and increases laminin expression, resulting in decreased astrocytoma cell motility. Pan-GFAP silencing leads to decreased cell spreading, increased integrin expression, and >100-fold increase in cell adhesion to laminin, demonstrating isoform-specific roles of GFAP in regulating extracellular matrix interactions.\",\n      \"method\": \"Isoform-specific shRNA silencing of GFAPα in astrocytoma cells; migration/motility assays; integrin and laminin expression analysis; cell adhesion assay\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — isoform-specific RNAi with multiple functional readouts (motility, adhesion, integrin expression), single lab\",\n      \"pmids\": [\"24696300\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"GFAPδ exchanges more slowly with the intermediate filament network than GFAPα as measured by FRAP; GFAPδ-induced IF network collapse further decreases exchange rates of both isoforms and alters cell morphology and focal adhesion size without affecting cell migration or proliferation.\",\n      \"method\": \"FRAP of fluorescently tagged GFAPα and GFAPδ in astrocytoma cells; immunostaining for focal adhesions; migration and proliferation assays\",\n      \"journal\": \"Cellular and molecular life sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — quantitative live-cell FRAP with multiple functional assays, single lab\",\n      \"pmids\": [\"27141937\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Gq-GPCR activation specifically in peripheral GFAP+ satellite glial cells (within sympathetic ganglia) leads to increased norepinephrine release, beta-1 adrenergic receptor activation in the heart, and consequent acceleration of heart rate and increased left ventricular contraction, demonstrating a functional role for GFAP+ glia in regulating cardiovascular function.\",\n      \"method\": \"Transgenic mice expressing hM3Dq DREADD in GFAP+ cells; pharmacological activation with clozapine N-oxide; cardiovascular measurements; beta-blocker pharmacological dissection\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-type-specific chemogenetic manipulation with pharmacological dissection of downstream mechanism, single lab\",\n      \"pmids\": [\"28138563\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"AxD-causing GFAP mutations in iPSC-derived human astrocytes cause GFAP aggregates, enlarged and perinuclearly localized endoplasmic reticulum and lysosomes, impaired extracellular ATP release, and attenuated calcium wave propagation, revealing that mutant GFAP disrupts intracellular vesicle regulation and astrocyte secretory function.\",\n      \"method\": \"iPSC-derived astrocytes from AxD patients with isogenic correction; RNA-seq; organelle morphology imaging; ATP release assay; calcium imaging\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — isogenic iPSC correction with multiple orthogonal methods (RNA-seq, organelle imaging, functional assays) in human cells; mechanistically rigorous\",\n      \"pmids\": [\"30355500\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"GFAP and vimentin deficiency (GFAP-/-Vim-/- mice) results in decreased Notch signal-sending competence in astrocytes and altered expression of Notch signaling pathway genes (Dlk2, Notch1, Sox2), demonstrating that astrocyte intermediate filaments regulate Notch signaling capacity.\",\n      \"method\": \"Single-cell RT-qPCR on freshly isolated astrocytes from GFAP-/-Vim-/- and wild-type mice; hippocampal entorhinal cortex lesion model\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout with single-cell gene expression analysis, specific pathway readout, single lab\",\n      \"pmids\": [\"26118771\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"GFAP is palmitoylated in vitro and in vivo at a unique site, cysteine-291; PPT1 is the depalmitoylating enzyme for GFAP; palmitoylated GFAP promotes astrocyte proliferation in vitro; in PPT1-knockin mice, hyperpalmitoylated GFAP drives astrogliosis and neurodegeneration, and mutating C291A attenuates astrogliosis and concurrent neurodegeneration.\",\n      \"method\": \"Palm-proteomics; in vitro palmitoylation assay; site-directed mutagenesis (C291A); PPT1-KI mouse model; astrocyte proliferation assays; immunohistology for astrogliosis markers\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro palmitoylation assay + site-directed mutagenesis + in vivo genetic mouse model with functional rescue; multiple orthogonal methods identifying unique modification site\",\n      \"pmids\": [\"33753498\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"GFAP and vimentin double-knockout (GFAP-/-Vim-/-) mice show more pronounced memory extinction compared to wildtype mice in IntelliCage reversal learning, while other learning and memory measures are comparable, indicating a specific role for astrocyte intermediate filaments in hippocampal circuit reorganization.\",\n      \"method\": \"GFAP-/-Vim-/- mice; open field, object recognition, Morris water maze, trace fear conditioning, IntelliCage reversal learning behavioral tests\",\n      \"journal\": \"Biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout with multiple behavioral tests; specific phenotype found in one paradigm, single lab\",\n      \"pmids\": [\"31063456\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"GFAP is the major type III intermediate filament protein of mature astrocytes that provides structural support and maintains cell shape; its expression is transcriptionally regulated by STAT3, NFI, SP1, NF-κB, MeCP2/SIN3A, and growth factors (TGF-β1, FGF-2) acting on defined promoter elements, and epigenetically controlled by histone acetylation; post-translationally, GFAP is palmitoylated at cysteine-291 (depalmitoylated by PPT1), with hyperpalmitoylation promoting astrocyte proliferation and astrogliosis; GFAP isoforms (GFAPα vs. GFAPδ) differ in filament network exchange dynamics and regulate focal adhesion size, cell morphology, and laminin-dependent motility; dominant missense mutations (e.g., R239C) cause Alexander disease through a gain-of-function mechanism involving filament network disorganization, decreased GFAP solubility, sequestration of chaperones αB-crystallin and HSP27 into Rosenthal fibers, JNK activation, impaired vesicle trafficking, and defective astrocyte ATP secretion and calcium signaling.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"GFAP is the principal type III intermediate filament protein of differentiated CNS astrocytes, forming the glial cytoskeleton that defines and maintains astrocyte shape [#0]. Its assembly into 10 nm filaments builds a dynamic network whose subunit exchange and organization are isoform-dependent: GFAP\\u03b4 exchanges more slowly than GFAP\\u03b1 and shifting the isoform ratio reorganizes the network, alters focal adhesion size and cell morphology [#21], and reprograms extracellular matrix engagement\\u2014changing plectin, laminin, and integrin levels to control adhesion and motility [#20]. Beyond structural support, the GFAP/vimentin filament system regulates astrocyte signaling competence, tuning Notch signal-sending capacity [#24] and contributing to hippocampal circuit plasticity underlying memory extinction [#26]. GFAP expression is tightly controlled at a defined astrocyte-specific promoter [#5, #17] through a developmental switch in which repressive MeCP2/SIN3A occupancy gives way to STAT3 recruitment of CBP/p300 and activating histone modifications [#16], and is further modulated by growth-factor and neurotransmitter inputs (TGF-\\u03b21 induction opposed by FGF-2; glutamate acting via mGluR2/3-TGF-\\u03b21-Smad signaling) [#6, #13]. Post-translationally, GFAP is palmitoylated at cysteine-291 and depalmitoylated by PPT1; hyperpalmitoylation drives astrocyte proliferation, astrogliosis, and neurodegeneration, which is attenuated by the C291A mutation [#25]. Dominant de novo missense mutations in GFAP cause Alexander disease through a gain-of-function mechanism [#8]: mutant (or excess) GFAP disorganizes the filament network and becomes detergent-insoluble [#10], forming Rosenthal-fiber inclusions that sequester the chaperones \\u03b1B-crystallin and HSP27, activate JNK stress signaling, and impair proteasome function [#12, #15], and in patient iPSC-derived astrocytes disrupt ER and lysosome morphology, ATP release, and calcium wave propagation [#23].\",\n  \"teleology\": [\n    {\n      \"year\": 1985,\n      \"claim\": \"Established the founding identity of GFAP as the structural intermediate filament protein that builds the astrocyte cytoskeleton, defining the molecular basis of astrocyte shape.\",\n      \"evidence\": \"Biochemical and immunocytochemical characterization of glial filaments in CNS astrocytes\",\n      \"pmids\": [\"2409105\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not address regulation of expression\", \"Does not address assembly dynamics or post-translational control\"]\n    },\n    {\n      \"year\": 1989,\n      \"claim\": \"Showed GFAP expression is not constitutive but dynamically driven by extrinsic cues, including trophic and developmental inputs, rather than being a fixed cell marker.\",\n      \"evidence\": \"dbcAMP labeling of astrocyte cultures; sciatic nerve transection with mRNA readout; insulin-titrated organotypic cerebellar cultures; pulse-chase turnover kinetics\",\n      \"pmids\": [\"2989328\", \"2769798\", \"1782546\", \"2279327\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not identify the promoter elements or transcription factors mediating these responses\", \"Mechanism linking signal to GFAP transcription unresolved\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Localized the regulatory logic of astrocyte-specific and injury-induced GFAP expression to a defined 5'-flanking promoter region, enabling dissection of its control elements.\",\n      \"evidence\": \"GFAP-promoter-lacZ transgenic mice with injury challenge\",\n      \"pmids\": [\"8120611\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve which transcription factors bind which elements\", \"Did not address chromatin-level regulation\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Defined Alexander disease as a dominant gain-of-function disorder of GFAP, distinguishing toxic-intermediate accumulation from simple loss of filament function.\",\n      \"evidence\": \"Mutation sequencing across patient cohorts; epistatic comparison with GFAP-null mice\",\n      \"pmids\": [\"12175861\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the molecular nature of the toxic species\", \"Did not link mutations to downstream cellular dysfunction\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Resolved that disease mutations act on network organization and solubility rather than on filament polymerization, and connected progenitor signaling to GFAP+ cell identity.\",\n      \"evidence\": \"R239C transfection across cell lines with Triton-X-100 extraction and in vitro filament assembly; LIF/BMP treatment and transgenic BMP modulation of SVZ progenitors\",\n      \"pmids\": [\"15840648\", \"16314487\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify the chaperone or stress pathways engaged by insoluble mutant GFAP\", \"GFAP+ progenitor heterogeneity not molecularly resolved\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Built a cellular pathogenic model linking mutant/excess GFAP accumulation to chaperone sequestration, JNK stress activation, proteasome impairment, and reduced astrocyte viability.\",\n      \"evidence\": \"Review synthesis plus primary chaperone co-localization and JNK assays; primary astrocytes from GFAP-overexpressing and R236H knock-in mice with proteasome and stress assays\",\n      \"pmids\": [\"17498694\", \"19146851\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causal order of chaperone sequestration vs JNK activation not established\", \"Did not address organelle or secretory dysfunction\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Mapped the transcriptional control of GFAP to discrete promoter elements and signaling inputs, establishing combinatorial astrocyte-specific and region-specific regulation.\",\n      \"evidence\": \"Transgenic promoter deletion/mutation analysis defining neuronal-silencer (C1.2) and region-specific (C1.1) elements and NFI/SP1/STAT3/NF-\\u03baB sites; reporter dissection of glutamate-mGluR2/3-TGF-\\u03b21-Smad activation\",\n      \"pmids\": [\"18240313\", \"18419760\", \"23832770\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not establish chromatin-state dynamics during differentiation\", \"Quantitative contribution of each factor in vivo not fully resolved\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Defined the epigenetic switch driving GFAP induction during astrocyte differentiation, converting a repressed promoter into an active one via chromatin remodeling.\",\n      \"evidence\": \"ChIP for MeCP2/SIN3A, STAT3, CBP/p300, Pol II and histone marks in differentiating NTera-2 cells; MeCP2 siRNA in developing rat brain; HDAC inhibitor and SR-protein studies\",\n      \"pmids\": [\"21779366\", \"24269336\", \"25128567\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Upstream trigger for SIN3A-MeCP2 departure not defined\", \"Link between histone acetylation state and isoform splicing only partially resolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Demonstrated that GFAP isoforms are functionally non-equivalent, with the GFAP\\u03b1/GFAP\\u03b4 ratio controlling network exchange dynamics, focal adhesions, ECM engagement, and motility.\",\n      \"evidence\": \"Isoform-specific shRNA silencing with adhesion/migration/integrin assays; FRAP of tagged GFAP\\u03b1 vs GFAP\\u03b4 with morphology readouts\",\n      \"pmids\": [\"24696300\", \"27141937\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism coupling filament exchange to focal-adhesion remodeling unresolved\", \"Relevance of isoform balance in vivo not established\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Showed in a human isogenic system that disease-mutant GFAP disrupts organelle morphology and astrocyte secretory function, extending pathogenesis beyond filament aggregation to ER/lysosome and ATP/calcium signaling defects.\",\n      \"evidence\": \"iPSC-derived AxD astrocytes with isogenic correction; RNA-seq, organelle imaging, ATP release and calcium imaging assays\",\n      \"pmids\": [\"30355500\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism linking filament aggregates to organelle enlargement not defined\", \"Did not address therapeutic reversibility\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Revealed signaling and behavioral roles of the astrocyte intermediate filament system beyond structure, including Notch signal-sending competence and hippocampal circuit plasticity.\",\n      \"evidence\": \"GFAP-/-Vim-/- mice with single-cell RT-qPCR and lesion model; behavioral battery including IntelliCage reversal learning\",\n      \"pmids\": [\"26118771\", \"31063456\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cannot separate GFAP-specific from vimentin contributions\", \"Molecular link between filament loss and Notch competence unresolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identified a specific reversible lipid modification of GFAP and its erasing enzyme, establishing palmitoylation as a driver of astrocyte proliferation, astrogliosis, and neurodegeneration.\",\n      \"evidence\": \"Palm-proteomics and in vitro palmitoylation assay; C291A site-directed mutagenesis; PPT1-knockin mouse with functional rescue and astrogliosis markers\",\n      \"pmids\": [\"33753498\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Palmitoyltransferase that adds the modification not identified\", \"Mechanistic link between palmitoylation and filament dynamics unresolved\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Extended GFAP+ glial function to the periphery, showing GFAP+ satellite glia in sympathetic ganglia modulate cardiovascular output through neurotransmitter release.\",\n      \"evidence\": \"hM3Dq DREADD in GFAP+ cells with CNO activation, cardiovascular measurement, and beta-blocker dissection\",\n      \"pmids\": [\"28138563\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not establish a direct role for GFAP protein itself versus the GFAP+ cell type\", \"Mechanism of neurotransmitter release control unresolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the GFAP filament network mechanically and biochemically couples to organelle positioning, secretory function, and signaling competence\\u2014and how palmitoylation, isoform balance, and disease mutations converge on these outputs\\u2014remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model linking filament organization to organelle/secretory defects\", \"Palmitoyltransferase for GFAP unidentified\", \"Causal hierarchy among aggregation, chaperone sequestration, JNK, and organelle dysfunction in Alexander disease not established\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [0, 10]},\n      {\"term_id\": \"GO:0008092\", \"supporting_discovery_ids\": [20, 21]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005856\", \"supporting_discovery_ids\": [0, 10]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [10, 15]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [8, 12, 23]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [16, 17]}\n    ],\n    \"complexes\": [\"Rosenthal fibers\"],\n    \"partners\": [\"CRYAB\", \"HSPB1\", \"PPT1\", \"VIM\", \"PLEC\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}